众生药业：子公司酮酰胺衍生物及其应用获发明专利证书，为口服抗新冠药物来瑞特韦片项目的核心专利
众生药业3月19日公告，近日，公司控股子公司众生睿创收到中华人民共和国国家知识产权局颁发的发明专利证书，发明名称为酮酰胺衍生物及其应用。本专利是众生睿创口服抗新型冠状病毒3CL蛋白酶抑制剂来瑞特韦片（商品名：乐睿灵®，研发代号：RAY1216）的化合物专利，属于该项目的核心专利。来瑞特韦片通过作用于新型冠状病毒（SARS-Cov-2）的3CL蛋白酶，抑制病毒多聚前体蛋白的切割，进而阻断病毒复制，达到抗新冠病毒的作用。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
Bullish Trends are Highly Manipulated, Says Crypto Analyst By CoinEdition
5 big deal reports: UBS offers to snap up Credit Suisse for $1 billion | Pro Recap By
Related News
